Hainan Honz Pharmaceutical Co (300086) - Net Assets

Latest as of September 2025: CN¥1.07 Billion CNY ≈ $157.10 Million USD

Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has net assets worth CN¥1.07 Billion CNY (≈ $157.10 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.88 Billion ≈ $274.92 Million USD) and total liabilities (CN¥805.18 Million ≈ $117.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Hainan Honz Pharmaceutical Co's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥1.07 Billion
% of Total Assets	57.14%
Annual Growth Rate	14.54%
5-Year Change	-27.25%
10-Year Change	-36.72%
Growth Volatility	155.61

Hainan Honz Pharmaceutical Co - Net Assets Trend (2007–2024)

This chart illustrates how Hainan Honz Pharmaceutical Co's net assets have evolved over time, based on quarterly financial data. Also explore 300086 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Hainan Honz Pharmaceutical Co (2007–2024)

The table below shows the annual net assets of Hainan Honz Pharmaceutical Co from 2007 to 2024. For live valuation and market cap data, see 300086 market cap overview.

Year	Net Assets	Change
2024-12-31	CN¥1.17 Billion ≈ $170.52 Million	-15.44%
2023-12-31	CN¥1.38 Billion ≈ $201.65 Million	+1.66%
2022-12-31	CN¥1.36 Billion ≈ $198.35 Million	-12.75%
2021-12-31	CN¥1.55 Billion ≈ $227.35 Million	-3.00%
2020-12-31	CN¥1.60 Billion ≈ $234.39 Million	0.00%
2019-12-31	CN¥1.60 Billion ≈ $234.40 Million	-3.13%
2018-12-31	CN¥1.65 Billion ≈ $241.97 Million	-13.91%
2017-12-31	CN¥1.92 Billion ≈ $281.05 Million	+2.57%
2016-12-31	CN¥1.87 Billion ≈ $274.03 Million	+1.68%
2015-12-31	CN¥1.84 Billion ≈ $269.49 Million	+2.05%
2014-12-31	CN¥1.80 Billion ≈ $264.07 Million	-0.30%
2013-12-31	CN¥1.81 Billion ≈ $264.88 Million	-3.39%
2012-12-31	CN¥1.87 Billion ≈ $274.16 Million	+1.06%
2011-12-31	CN¥1.85 Billion ≈ $271.29 Million	+1.39%
2010-12-31	CN¥1.83 Billion ≈ $267.58 Million	+660.36%
2009-12-31	CN¥240.49 Million ≈ $35.19 Million	+59.89%
2008-12-31	CN¥150.41 Million ≈ $22.01 Million	+29.79%
2007-12-31	CN¥115.89 Million ≈ $16.96 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hainan Honz Pharmaceutical Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 93513.2% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	CN¥455.12 Million	39.93%
Other Components	CN¥949.67 Million	83.31%
Total Equity	CN¥1.14 Billion	100.00%

Hainan Honz Pharmaceutical Co Competitors by Market Cap

The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their market capitalization.

Company	Market Cap
Ventec International Group Co Ltd TW:6672	$492.88 Million
First Trust High Yield Opportunities 2027 Term Fund NYSE:FTHY	$493.13 Million
Hollyland China Electronics Technology Corp Ltd SHE:002729	$493.18 Million
Johnson Outdoors Inc NASDAQ:JOUT	$493.23 Million
Gazit Globe Ltd TA:GZT	$492.80 Million
Grid Dynamics Holdings Inc NASDAQ:GDYN	$492.72 Million
Zhejiang Wufangzhai Industry Co. Ltd. A SHG:603237	$492.55 Million
Jinsanjiang (Zhaoqing) Silicon Material Company Limited SHE:301059	$492.49 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hainan Honz Pharmaceutical Co's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,344,759,445 to 1,139,922,413, a change of -204,837,032 (-15.2%).
Net loss of 216,208,514 reduced equity.
Dividend payments of 19,872,395 reduced retained earnings.
Other factors increased equity by 31,243,877.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-216.21 Million	-18.97%
Dividends Paid	CN¥19.87 Million	-1.74%
Other Changes	CN¥31.24 Million	+2.74%
Total Change	CN¥-	-15.23%

Book Value vs Market Value Analysis

This analysis compares Hainan Honz Pharmaceutical Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.96x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 19.27x to 2.96x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	CN¥0.38	CN¥7.40	x
2008-12-31	CN¥0.45	CN¥7.40	x
2009-12-31	CN¥0.71	CN¥7.40	x
2010-12-31	CN¥4.54	CN¥7.40	x
2011-12-31	CN¥3.94	CN¥7.40	x
2012-12-31	CN¥3.98	CN¥7.40	x
2013-12-31	CN¥3.84	CN¥7.40	x
2014-12-31	CN¥3.83	CN¥7.40	x
2015-12-31	CN¥3.91	CN¥7.40	x
2016-12-31	CN¥4.00	CN¥7.40	x
2017-12-31	CN¥4.11	CN¥7.40	x
2018-12-31	CN¥3.43	CN¥7.40	x
2019-12-31	CN¥3.33	CN¥7.40	x
2020-12-31	CN¥3.35	CN¥7.40	x
2021-12-31	CN¥3.34	CN¥7.40	x
2022-12-31	CN¥2.93	CN¥7.40	x
2023-12-31	CN¥2.99	CN¥7.40	x
2024-12-31	CN¥2.50	CN¥7.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hainan Honz Pharmaceutical Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -18.97%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -45.73%
• Asset Turnover: 0.24x
• Equity Multiplier: 1.73x
Recent ROE (-18.97%) is below the historical average (5.21%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	29.51%	35.64%	0.68x	1.22x	CN¥22.61 Million
2008	32.93%	36.46%	0.66x	1.37x	CN¥34.48 Million
2009	40.57%	44.60%	0.74x	1.22x	CN¥73.53 Million
2010	7.62%	44.30%	0.17x	1.04x	CN¥-43.54 Million
2011	-0.06%	-0.37%	0.15x	1.11x	CN¥-177.88 Million
2012	1.26%	6.12%	0.19x	1.10x	CN¥-156.42 Million
2013	0.86%	4.80%	0.16x	1.10x	CN¥-157.85 Million
2014	3.60%	15.20%	0.21x	1.12x	CN¥-110.29 Million
2015	3.87%	16.64%	0.20x	1.19x	CN¥-108.01 Million
2016	2.56%	9.79%	0.22x	1.22x	CN¥-133.91 Million
2017	3.00%	8.31%	0.30x	1.21x	CN¥-129.54 Million
2018	0.87%	1.51%	0.40x	1.41x	CN¥-141.05 Million
2019	-1.77%	-2.62%	0.46x	1.46x	CN¥-176.31 Million
2020	0.62%	1.01%	0.35x	1.74x	CN¥-140.91 Million
2021	0.73%	1.31%	0.34x	1.63x	CN¥-139.41 Million
2022	-14.25%	-35.01%	0.23x	1.74x	CN¥-319.20 Million
2023	0.86%	1.56%	0.34x	1.61x	CN¥-122.95 Million
2024	-18.97%	-45.73%	0.24x	1.73x	CN¥-330.20 Million

Industry Comparison

This section compares Hainan Honz Pharmaceutical Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $1,347,197,696
Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hainan Honz Pharmaceutical Co (300086)	CN¥1.07 Billion	29.51%	0.75x	$492.83 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$2.84 Billion	-41.97%	9.13x	$1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$638.89 Million	0.88%	0.70x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.05 Billion	10.46%	0.19x	$5.18 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.81 Billion
Wedge Industrial Co Ltd (000534)	$1.29 Billion	11.69%	1.47x	$2.95 Billion
Yunnan Baiyao Group Co Ltd (000538)	$35.11 Million	18.13%	0.80x	$13.85 Billion
Hainan Haiyao Co Ltd (000566)	$5.08 Billion	1.71%	1.08x	$949.23 Million
Tus Pharmaceutical Group Co Ltd (000590)	$141.91 Million	11.01%	0.32x	$391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$994.58 Million	2.01%	2.11x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$332.48 Million	26.89%	0.68x	$3.30 Billion

About Hainan Honz Pharmaceutical Co

SHE:300086 China Drug Manufacturers - Specialty & Generic

Market Cap

$492.83 Million

CN¥3.37 Billion CNY

Market Cap Rank

#12612 Global

#3932 in China

Share Price

CN¥7.40

Change (1 day)

+2.49%

52-Week Range

CN¥4.79 - CN¥13.71

All Time High

CN¥17.75